1. Scrip
  2. >>Archive

Podcast: Navigating IND Applications & Pre-IND Meetings: Key Considerations And Misconceptions

Business concept - high speed abstract MRT track of motion light for background in tokyo, japan

Advancing Investigational New Drugs (INDs) can be a complex process, especially for smaller companies. Listen to your free podcast now as Marcus Delatte, PhD, Vice President at Allucent and Harshini Neelakantan, Executive Director at Ridgeline Therapeutics discuss best practices and considerations for leveraging your pre-IND meeting and submitting a successful IND application.

Listen now for insights into:

  • Current trends and challenges related to IND submissions
  • The purpose and benefits of pre-IND meetings with regulatory bodies
  • Indicators that should prompt companies to request a pre-IND meeting
  • The role of consultants in supporting sponsors in pre-IND meetings
  • Getting the most from your pre-IND meeting and tips for IND application success
  • How IND submissions will evolve in the future

Citeline · Navigating IND Applications & Pre-IND Meetings: Key Considerations And Misconceptions

Citeline · Navigating IND Applications & Pre-IND Meetings: Key Considerations And Misconceptions

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Sponsored by:

A Crossroads for Global Health: Strengthening the Future of Vaccines

Learn how advances in vaccine adjuvants are shaping the future of global health and driving more effective immunization strategies

Sponsored by:

A Crossroads for Global Health: Strengthening the Future of Vaccines

Learn how advances in vaccine adjuvants are shaping the future of global health and driving more effective immunization strategies

Sponsored by:

Podcast Series: Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials

Insights from Novotech on Evolving Trends Impacting Global Clinical Development

Sponsored by:

Meeting the demands of the global biologics market

Lonza is addressing the growing global demand for biologics by utilizing its expert teams and the advanced capabilities of its newly acquired large-scale manufacturing site in Vacaville, California. Joanna McCafferty, Director of Commercial Development, shares more in this brief video. Ask ChatG